Home > Drugs A – Z > Fluorescein (Injection)
  • We are sorry, but NCBI web applications do not support your browser and may not function properly. More information

Fluorescein (Injection)

Helps certain parts of the eye become more visible during tests.

What works?

Learn more about the effects of these drugs. The most reliable research is summed up for you in our featured article.

Brand names include
AK-Fluor, Angioscein, Fluorescite
Drug classes About this
Disclosing Agent

What works? Research summarized

Evidence reviews

Fluorescein-tear breakup time as an assessment of efficacy of tear replacement therapy in dry eye patients: a systematic review and meta-analysis

PURPOSE: To review outcomes of studies where fluorescein-tear breakup time (fTBUT) measurements had been made before and after treatment with artificial tears.

Outcomes of Genetic Testing in Adults with a History of Venous Thromboembolism

To address whether Factor V Leiden (FVL) testing alone, or in combination with prothrombin G20210A testing, leads to improved clinical outcomes in adults with a personal history of venous thromboembolism (VTE) or to improved clinical outcomes in adult family members of mutation-positive individuals.

Screening for Visual Impairment in Older Adults: Systematic Review to Update the 1996 U.S. Preventive Services Task Force Recommendation [Internet]

Impaired visual acuity is common in older adults. Screening for impaired visual acuity in primary care settings could identify older adults who are unaware of or do not report vision problems, and lead to interventions to improve vision, function and quality of life.

See all (18)

Summaries for consumers

Injections of anti‐vascular endothelial growth factor for advanced diabetic retinopathy

Diabetic retinopathy is a problem of the back of the eye that occurs in people with diabetes. In later stages of the disease, new blood vessels grow in the back of the eye and cause problems with vision. This advanced form of the disease is known as proliferative diabetic retinopathy. Anti‐VEGF has been developed to block the growth of these new vessels. It has to be injected into the eye.

Eyedrops made from autologous serum as a treatment for dry eye

We conducted a wide range of searches for relevant trials in April 2013. We identified four randomized controlled trials with a total of 72 participants with dry eye from Chile, Australia and Japan. The trials compared autologous serum eye drops to traditional artificial tears for the treatment of dry eye. The results from the four trials could not be combined in analysis due to the variation in participant populations, follow‐up intervals, and incomplete reporting of treatment outcomes. None of the included trials reported outcomes for the primary outcome of this review, the change in participant‐reported symptoms after one month of treatment. Some improvements in participant‐reported outcomes and tear film stability were seen in two trials after two weeks, but not in the other two trials or at longer follow‐up periods. Autologous serum eye drops did not provide a benefit based on other clinical assessments of the surface of the eye compared to traditional artificial tears. Outcomes for quality or life and costs were not reported in any of the trials. One study reported that no serious harms were related to using autologous serum eye drops while the other studies did not discuss whether any adverse events occurred. Overall the results from these studies do not provide consistent information as to whether autologous serum eye drops are safe and effective for the treatment of dry eye. Future trials are needed using appropriate study designs to address participant‐centered outcomes, to determine the effects of autologous serum eye drops in the treatment of dry eye.

Retinoblastoma Treatment (PDQ®): Patient Version

Expert-reviewed information summary about the treatment of retinoblastoma in children.

See all (4)

PubMed Health Blog...

read all...